Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1989-8-25
|
pubmed:abstractText |
A randomized, multi-centre trial was carried out in 152 hospitalized women with pelvic inflammatory disease to evaluate the efficacy and tolerability of amoxycillin/clavulanic acid compared with that of a standard regimen using three antimicrobial agents (aminopenicillin, an aminoglycoside and metronidazole). Seventy patients initially received 3 to 4 intravenous doses per day of 1 g amoxycillin/200 mg clavulanic acid (mean 7.7 days) and then 4 to 6 tablets per day of 500 mg amoxycillin/125 mg clavulanic acid (mean 11.2 days). The other group of 82 patients initially received parenteral therapy daily (mean 7.7 days) with a combination of 3 to 4 g amoxycillin or ampicillin, 160 mg gentamicin (or 150 mg dibekacin or tobramycin) and 1.5 g metronidazole, and then oral therapy with 2 to 3 g amoxycillin or ampicillin and 1 to 1.5 g metronidazole daily (11.1 days). Clinical results, assessed at discharge from hospital (mean 10 days in both groups), were comparable in both groups, with 96% complete or partial response and no failures in the amoxycillin/clavulanic acid group, and 90% complete or partial successes and 5 failures with the triple therapy regimen. Both treatments were well tolerated and very few side-effects were reported.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aminoglycosides,
http://linkedlifedata.com/resource/pubmed/chemical/Amoxicillin,
http://linkedlifedata.com/resource/pubmed/chemical/Amoxicillin-Potassium Clavulanate...,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Clavulanic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Metronidazole,
http://linkedlifedata.com/resource/pubmed/chemical/Penicillins
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0308-051X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
5
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
312-9
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2664816-Adult,
pubmed-meshheading:2664816-Aminoglycosides,
pubmed-meshheading:2664816-Amoxicillin,
pubmed-meshheading:2664816-Amoxicillin-Potassium Clavulanate Combination,
pubmed-meshheading:2664816-Anti-Bacterial Agents,
pubmed-meshheading:2664816-Clavulanic Acids,
pubmed-meshheading:2664816-Clinical Trials as Topic,
pubmed-meshheading:2664816-Double-Blind Method,
pubmed-meshheading:2664816-Drug Therapy, Combination,
pubmed-meshheading:2664816-Female,
pubmed-meshheading:2664816-Humans,
pubmed-meshheading:2664816-Metronidazole,
pubmed-meshheading:2664816-Pelvic Inflammatory Disease,
pubmed-meshheading:2664816-Penicillins,
pubmed-meshheading:2664816-Random Allocation
|
pubmed:year |
1989
|
pubmed:articleTitle |
Amoxycillin/clavulanic acid ('Augmentin') compared with a combination of aminopenicillin, aminoglycoside and metronidazole in the treatment of pelvic inflammatory disease.
|
pubmed:affiliation |
Hôpital Lariboisière, Paris, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|